GlassScriptPhysician profile
Jeremy Ryan Chang
NPI 1679004691
$690.14
in general payments reported to CMS, 2019-2025
14 companies · $568 in 2025
The $568 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.63 · 2024: $106 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $673.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $229.58 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $69.01 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.21 | 2024-2025 | |
| Exact Sciences Corporation | $58.64 | 2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $51.71 | 2025 | Veozah |
| Mayne Pharma Commercial LLC | $49.06 | 2025 | |
| Intuitive Surgical, INC. | $29.01 | 2025 | |
| Organon LLC | $27.10 | 2022-2025 | Nexplanon |
| Hologic Sales and Service, LLC | $25.47 | 2025 | Aptima |
| Janssen Pharmaceuticals, INC | $23.13 | 2025 | Spravato |
| Lilly USA, LLC | $18.90 | 2025 | Mounjaro, Zepbound |
| Sumitomo Pharma America, INC. | $17.97 | 2025 | Myfembree |
| Exeltis, USA INC. | $14.76 | 2025 | Slynd |
| Coopersurgical, INC. | $13.59 | 2025 | Paragard T 380a |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.